# US 2025/0084091 A1 · Inhibitors of sars-cov-2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084091 A1
- Document ID: US20250084091A1
- Status: Published application
- Kind: A1
- Application number: 18/558,908
- Filed: 2022-05-04
- Published: 2025-03-13
- Earliest claimed: 2021-05-04
- Assignees: The Texas A&M University System
- Applicants: The Texas A&M University System
- Inventors: James C. Sacchettini; Nian E. Zhou; Maloy Kumar Parai; Joonyoung Shin; Jeremy Lee Wood; Inna V. Krieger; Armando Flores; Arjun Acharya; Zhe Shi; Xuelin Bian; Su TANG; Radha Bam; Pradeep Kumar Jaiswal
- Web page: https://patentgrep.com/patent/US20250084091A1

## CPC

- C07D 487/08: Bridged systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 209/34: in position 2
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/36: Radicals substituted by singly-bound nitrogen atoms (nitro radicals C07D213/26)
- C07D 213/57: Nitriles
- C07D 213/71: to which a second hetero atom is attached
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/81: Amides; Imides
- C07D 213/82: in position 3
- C07D 213/84: Nitriles
- C07D 215/50: attached in position 4
- C07D 215/54: attached in position 3
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 239/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 241/08: with oxygen atoms directly attached to ring carbon atoms
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 265/30: not condensed with other rings
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 277/62: Benzothiazoles
- C07D 295/192: from aromatic carboxylic acids
- C07D 295/26: Sulfur atoms
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/70: attached in position 2
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds and methods for the treatment of coronavirus infection. The compounds can function as an inhibitor of the main protease (Mpro) of coronaviruses. The compounds can include diphenylmethyl piperazine derivatives, diphenylmethyl piperidine derivatives, diphenylmethylidene piperidine derivatives, tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen derivatives, tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen derivatives, 6,11-dihydrobenzo[c][1]benzoxepin derivatives, 6,11-dihydrobenzo[c][1]benzothiepin derivatives, 5,5-dioxo-6,11-dihydrobenzo[c][1]benzothiepin derivatives, and 6-oxo-5,11-dihydrobenzo[c][1]benzazepin derivatives, as well as pharmaceutically acceptable salts, hydrates, and prodrugs thereof.

## Claims

### Claim 1

A compound defined by Formula (I) below.
or a pharmaceutically acceptable salt or prodrug thereof, wherein, as valence and stability permit,
Ar1 and Ar2 are independently selected from aryl or heteroaryl, each optionally substituted with one or more substituents individually chosen from R5;
X is chosen from the following groups:
Y is selected from —CO—, —SO2—, —S(═O)—, —S(O)2NR6—, —S(═O)(=NR6)—, and —CH2—;
R is selected from aryl, heteroaryl, cycloalkyl, and cycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R5;
R5 is chosen from hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, heterodialkylaminocarbonyl, sulfonamido, and sulfoximino; and
R6 is chosen from hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, each optionally substituted with one or more substituents individually chosen from R5.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Ar1 and Ar2 are each independently a 5-7 membered aryl or heteroaryl group, each optionally substituted with one or more substituents individually chosen from R5.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Ar1 and Ar2 are each independently chosen from phenyl and pyridine, each optionally substituted with one or more substituents individually chosen from R5.

### Claim 4 (depends on 1)

The compound of claim 1, wherein X is chosen from the following groups:

### Claim 5 (depends on 1)

The compound of claim 1, wherein X is chosen from the following groups:

### Claim 6 (depends on 1)

The compound of claim 1, wherein X is

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is

### Claim 8 (depends on 1)

The compound of claim 1, wherein Y is —CO—.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R is a 5-10 membered ring (e.g., a 5-7 membered ring) optionally substituted with one or more substituents individually chosen from R5.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R is chosen from a phenyl, pyridine, thiophen, furan, pyrrole, imidazole, thiazole, oxazole, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, benzoxazole, benzothiozole, benzimidazole, piperazine, piperidine, morpholine, quinuclidine, pyrrolo-pyridine, imidazo-pyridine, pyrazolo-pyridine, furo-pyridine and thieno-pyridine, or pyrrolidine group each optionally substituted with one or more substituents individually chosen from R5.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R is a pyrrlo-pyridine or azaindole group optionally substituted with one or more substituents individually chosen from R5.

### Claim 12

A compound defined by Formula (II) below
or a pharmaceutically acceptable salt or prodrug thereof, wherein, as valence and stability permit,
Ar1 and Ar2 are independently selected from aryl or heteroaryl, each optionally substituted with one or more substituents individually chosen from R5;
Y is selected from —CO—, —SO2—, —S(═O)—, —S(O)2NR6—, —S(═O)(=NR6)—, and —CH2—;
R is selected from aryl, heteroaryl, cycloalkyl, and cycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R5;
R5 is chosen from hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, heterodialkylaminocarbonyl, sulfonamido, and sulfoximino; and
R6 is chosen from hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, each optionally substituted with one or more substituents individually chosen from R5.

### Claim at position 13

13-18. (canceled)

### Claim 19

A compound defined by any of Formula (III)—(XI)
pharmaceutically acceptable salts or prodrugs thereof, wherein, as valence and stability permit,
X is chosen from the following groups:
Y is selected from —CO—, —SO2—, —S(═O)—, —S(O)2NR6—, —S(═O)(=NR6)—, and —CH2—;
R is selected from aryl, heteroaryl, cycloalkyl, and cycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R5;
R1, R2, R3, and R4 are each individually chosen from hydrogen, hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;
R5 is chosen from hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, heterodialkylaminocarbonyl, sulfonamido, and sulfoximino; and
R6 is chosen from hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, each optionally substituted with one or more substituents individually chosen from R5.

### Claim at position 15

20-26. (canceled)

### Claim 27

A compound defined by Formula (XII) below
or a pharmaceutically acceptable salt or prodrug thereof, wherein, as valence and stability permit,
Ar1 and Ar2 are independently selected from aryl or heteroaryl, each optionally substituted with one or more substituents individually chosen from R5;
X is chosen from the following groups:
Y is selected from —CO—, —SO2—, —S(═O)—, —S(O)2NR6—, —S(═O)(=NR6)—, and —CH2—;
R is selected from aryl, heteroaryl, cycloalkyl, and cycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R5; and
R5 is chosen from hydroxy, halogen, —CN, —NO2, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, heterodialkylaminocarbonyl, sulfonamido, and sulfoximino; and
R6 is chosen from hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, each optionally substituted with one or more substituents individually chosen from R5.

### Claim at position 17

28-33. (canceled)

### Claim 34 (depends on 1)

The compound of claim 1, wherein the compound is described in Table 1.

### Claim 35 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 36 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound defined by claim 1.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the composition further comprises a cytochrome P450 3A4 (CYP-3A4) inhibitor or ritonavir or a pharmaceutical acceptable salt, ester, solvate, prodrug, or a derivative thereof.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

A method of treating or preventing a coronavirus infection in a subject, the method comprising administering a therapeutically effective amount of a compound defined by claim 1 to the subject.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

A method of inhibiting a coronavirus main protease, the method comprising contacting the coronavirus with an effective amount of a compound defined by claim 1.

### Claim 42

(canceled)
